Drug Efficacy And TolerabilityInitial fear was likely overblown as its weight loss efficacy was not that scary as QD and the tolerability on BID may not be optimal.
Drug Side EffectsRoche's CT-388 program shows high rates of nausea, diarrhea, vomiting, and constipation, which may limit its dose optimization.
Stock PerformanceThe stock is trading down ~10% although the data is positive and compares favorably to Rezdiffra (resmetirom).